MétaCan
Menu
Back to cohort
Record W4405301403 · doi:10.1200/po-24-00407

Clinical Utility of Genomic Sequencing for Hereditary Cancer Syndromes: An Observational Cohort Study

2024· article· en· W4405301403 on OpenAlexaff
Salma Shickh, Chloe Mighton, Marc Clausen, Jordan Sam, Daena Hirjikaka, Emma Reble, Tracy Graham, Seema Panchal, Andrea Eisen, Christine Elser, Kasmintan A. Schrader, Nancy N. Baxter, Andreas Laupacis, Jordan Lerner‐Ellis, Raymond H. Kim, Yvonne Bombard, Susan Randall Armel, Melyssa Aronson, Kenneth Bond, José‐Mario Capo‐Chichi, June Carroll, Timothy Caulfield, Tammy Clifford, Iris Cohn, Irfan A. Dhalla, Craig C. Earle, Michael F. Evans, Emily Glogowski, Elena Greenfeld, Jada G. Hamilton, Wanrudee Isaranuwatchai, Monika Kastner, Chantal F. Morel, Michelle Mujoomdar, Abdul Noor, Kenneth Offit, Mark E. Robson, Stephen W. Scherer, Adena Scheer, Terrence Sullivan, Kevin E. Thorpe

Bibliographic record

VenueJCO Precision Oncology · 2024
Typearticle
Languageen
FieldBiochemistry, Genetics and Molecular Biology
TopicGenomics and Rare Diseases
Canadian institutionsPrincess Margaret Cancer CentreOntario Institute for Cancer ResearchHospital for Sick ChildrenUniversity of British ColumbiaLunenfeld-Tanenbaum Research InstituteMount Sinai HospitalHealth Sciences CentreSunnybrook Health Science CentreUniversity Health NetworkUniversity of TorontoSt. Michael's Hospital
Fundersnot available
KeywordsMedicineCancerObservational studyBreast cancerFamily historyInternal medicineClinical trialCohortGenetic testingGenetic counselingOncologyGeneticsBiology

Abstract

fetched live from OpenAlex

PURPOSE Genomic sequencing (GS) is increasingly used to improve diagnoses and inform targeted therapies. GS can also be used to identify the 10% of cancer patients with an underlying hereditary cancer syndrome (HCS), who can benefit from surveillance and preventive surgery that reduce morbidity/mortality. However, the evidence on clinical utility of GS for HCS is limited: we aimed to fill this gap by assessing yield of all cancer results and associated recommendations for patients undergoing GS for HCS. MATERIALS AND METHODS An observational chart review and survey were conducted for cancer patients with previous uninformative cancer gene panel results, who received GS as part of the Incidental Genomics Trial (ClinicalTrials.gov identifier: NCT03597165 ). Descriptive statistics were used to describe demographics and clinical history. Proportions were calculated to compare frequencies of result types and recommendations made and followed. RESULTS A total of 276 patients were eligible and included. Participants were mostly female (n = 240), European (n = 158), and with breast cancer history (n = 168). Yield: 25 patients (9.1%) received ≥1 pathogenic/likely pathogenic variant, 246 (89%) received ≥1 variant of uncertain significance (VUS), and 27 (10%) were negative. Most pathogenic variants (20/26) were in low/moderate cancer risk genes. The mean number of VUS was 2.7/patient and higher in non-Europeans versus Europeans (3.5 v 2.5, P < .05). Recommendations: Pathogenic variants triggered 100 recommendations in 21/25 patients; most were for genetic counseling, communication to relatives, and cascade testing. CONCLUSION GS provided a modest increase in utility after first-tier cancer gene panels, at the cost of a high frequency of uncertain results. Furthermore, most positives were low/moderate cancer risk results that did not have corresponding evidence-based, management guidelines.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.000
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.158
Threshold uncertainty score0.447

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0010.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.144
GPT teacher head0.444
Teacher spread0.299 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations1
Published2024
Admission routes1
Has abstractyes

Explore more

Same venueJCO Precision OncologySame topicGenomics and Rare DiseasesFrench-language works237,207